CD140b and CD73 are markers for human induced pluripotent stem cell‐derived erythropoietin‐producing cells
CD140b and CD73 are markers for human induced pluripotent stem cell‐derived erythropoietin‐producing cells
复制标题
CD140b 和 CD73 是人诱导多能干细胞衍生的促红细胞生成素生成细胞的标记物
DOI：
10.1002/2211-5463.12800
复制
发表时间：
2019
期刊：
影响因子：
2.6
通讯作者：
Naagamatsu T. et al.
中科院分区：
文献类型：
--
作者：
Nishimoto S;Mizuno T;Naagamatsu T. et al.
重组人促红细胞生成素（rhEPO）治疗慢性肾病肾性贫血。然而，一些贫血患者对rhEPO反应不佳，这强调了对更具生物相容性的EPO的需求。人类诱导多能干细胞（hiPSC）衍生的EPO生成细胞（EPO细胞）已被修改为肝细胞的分化方案。然而，缺乏hiPSC - EPO细胞的标记物，使得纯化hiPSC - EPO细胞变得困难，因此难以优化EPO的产生和移植所需的细胞计数。为了解决这些问题，我们研究了CD140b和CD73是否可以作为hiPSC‐EPO细胞的标记物。在培养第13天，我们通过免疫组织化学和酶联免疫吸附法检测了hiPSC - EPO细胞中EPO、CD140b和CD73的表达以及细胞上清中EPO的浓度，发现CD140b和CD73的表达水平与EPO水平相关。此外，观察到CD140b+CD73+细胞率与EPO浓度相关。因此，我们的研究结果表明CD140b和CD73可能是hiPSC - EPO细胞的标记物。
Renal anemia in chronic kidney disease is treated with recombinant human erythropoietin (rhEPO). However, some patients with anemia do not respond well to rhEPO, emphasizing the need for a more biocompatible EPO. Differentiation protocols for hepatic lineages have been modified to enable production from human induced pluripotent stem cell (hiPSC)‐derived EPO‐producing cells (EPO cells). However, markers for hiPSC‐EPO cells are lacking, making it difficult to purify hiPSC‐EPO cells and therefore to optimize EPO production and cell counts for transplantation. To address these issues, we investigated whether CD140b and CD73 could be used as markers for hiPSC‐EPO cells. We measured the expression of EPO, CD140b, and CD73 in hiPSC‐EPO cells and the EPO concentration in the cell supernatant by immunohistochemistry and enzyme‐linked immunosorbent assays on culture day 13, revealing that expression levels of CD140b and CD73 are correlated with the level of EPO. In addition, rates of CD140b+CD73+cells were observed to be correlated with the concentration of EPO. Thus, our results suggest that CD140b and CD73 may be markers for hiPSC‐EPO cells.